Prevalence of Replication of Human Herpes Virus 6 (HHV6) in Blood and Skin During Exanthemia, in Patients With Hemopathy. Is There a Correlation With the Etiology of the Exanthema? (REPLIPO)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03102905 |
Recruitment Status : Unknown
Verified March 2017 by Centre Hospitalier Universitaire, Amiens.
Recruitment status was: Recruiting
First Posted : April 6, 2017
Last Update Posted : April 6, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
HHV6 Exanthema Hemopathy | Other: Measurement of the prevalence of the positivity of cutaneous HHV6 quantitative PCR in the cohort studied. |
Study Type : | Observational |
Estimated Enrollment : | 45 participants |
Observational Model: | Cohort |
Time Perspective: | Retrospective |
Official Title: | Prevalence of Replication of Human Herpes Virus 6 (HHV6) in Blood and Skin During Exanthemia, in Patients With Hemopathy. Is There a Correlation With the Etiology of the Exanthema? |
Actual Study Start Date : | December 13, 2016 |
Estimated Primary Completion Date : | June 13, 2017 |
Estimated Study Completion Date : | June 13, 2017 |
- Other: Measurement of the prevalence of the positivity of cutaneous HHV6 quantitative PCR in the cohort studied.
To evaluate the prevalence of the positivity of HHV6 PCR in the skin, during the exanthema in patients hospitalized for haemopathy.
- Measurement of the prevalence of the positivity of cutaneous HHV6 quantitative PCR in the cohort studied. [ Time Frame: 1 day ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Older Adult |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Supported for any type of hemopathy.
- Allograft, autografted or ungrafted haematopoietic stem cells
- Having presented an exanthema during hospitalization, for which a cutaneous biopsy had been performed
- Having had a blood test of the HHV6 virus by PCR at least within the previous 40 days or following the rash.
- Age greater than or equal to 18 years
- Patient informed of the protocol by post, not having refused within one month of sending the said courier.
Exclusion Criteria:
- Patient who refused the search.
- Patient whose HHV6 PCR in the blood was carried out at a distance of more than 40 days from the skin biopsy.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03102905
Contact: Guillaume CHABY, Dr | +33322455846 | chaby.guillaume@chu-amiens.fr |
France | |
CHU Amiens Picardie | Recruiting |
Amiens, Picardie, France, 80054 | |
Contact: Guillaume CHABY, Dr +33322455846 chaby.guillaume@chu-amiens.fr |
Responsible Party: | Centre Hospitalier Universitaire, Amiens |
ClinicalTrials.gov Identifier: | NCT03102905 |
Other Study ID Numbers: |
PI2016_843_0017 |
First Posted: | April 6, 2017 Key Record Dates |
Last Update Posted: | April 6, 2017 |
Last Verified: | March 2017 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Exanthema Skin Diseases |